
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular, or as to the action to be taken, you should consult your stockbroker or other licensed securities dealer, bank manager, solicitor, professional accountant or other professional advisers.

If you have sold or transferred all your shares in **Jinhai Medical Technology Limited** (the “Company”), you should at once hand this circular and the accompanying form of proxy to the purchaser(s) or transferee(s) or to the bank, stockbroker or licensed securities dealer or other agent through whom the sale or transfer was effected for transmission to the purchaser(s) or transferee(s).

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

This circular appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities mentioned herein.

Jinhai Medical Technology Limited

今海醫療科技股份有限公司

(Incorporated in the Cayman Islands with members' limited liability)

(Stock Code: 2225)

PROPOSED SUBDIVISION OF SHARES; AND NOTICE OF EXTRAORDINARY GENERAL MEETING

Financial Adviser to the Company



Fortune Financial Capital Limited

Capitalised terms used in this cover page shall have the same meanings as those defined in the section headed “Definitions” in this circular, unless the context otherwise requires.

A letter from the Board is set out on pages 3 to 9 of this circular.

A notice convening the extraordinary general meeting of the Company (the “EGM”) to be held at Block 3 East, 1275 Meichuan Road, Putuo District, Shanghai, China, on Tuesday, 10 December 2024 at 3:00 p.m. is set out on pages 12 to 13 of this circular.

A form of proxy for use at the EGM is enclosed. Whether or not you are able to attend the EGM, you are requested to complete, sign and return the accompanying form of proxy in accordance with the instructions printed thereon to the Company’s Hong Kong branch share registrar, Boardroom Share Registrars (HK) Limited at Room 2103B, 21/F, 148 Electric Road, North Point, Hong Kong as soon as possible and in any event not less than 48 hours before the time appointed for the holding of the EGM (or any adjournment thereof).

Completion and return of the form of proxy will not preclude you from attending and voting in person at the EGM (or any adjournment thereof) should you so wish.

This circular will remain on the Stock Exchange’s website at www.hkexnews.hk in the case of this circular, on the “Latest Company Announcements” page for at least seven days from the day of its posting. This circular will also be published on the Company’s website at www.jin-hai.com.hk.

References to time and dates in this circular are to Hong Kong time and dates.

22 November 2024

CONTENTS

	<i>Pages</i>
DEFINITIONS	1
LETTER FROM THE BOARD	3
APPENDIX I – EXPECTED TIMETABLE OF THE SHARE SUBDIVISION	10
NOTICE OF EXTRAORDINARY GENERAL MEETING	12

DEFINITIONS

In this circular, unless otherwise defined or the context otherwise requires, the following expressions have the following meanings:

“Articles of Association”	the articles of association of the Company as amended, supplemented and otherwise modified from time to time;
“Board”	the board of Directors of the Company;
“Business Day(s)”	any day(s) (other than a Saturday, Sunday or public holiday) on which licensed banks are generally open for business in Hong Kong throughout their normal business hours;
“CCASS”	the Central Clearing and Settlement System established and operated by HKSCC;
“Company”	Jinhai Medical Technology Limited, a company incorporated in the Cayman Islands with limited liability, the issued Shares of which are listed on the Main Board of the Stock Exchange (stock code: 2225);
“Director(s)”	director(s) of the Company;
“EGM”	the extraordinary general meeting of the Company to be convened and held at Block 3 East, 1275 Meichuan Road, Putuo District, Shanghai, China, on Tuesday, 10 December 2024 at 3:00 p.m., notice of which is set out on pages 12 to 13 of this circular, and any adjournment thereof;
“Group”	the Company and its subsidiaries;
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong;
“HKSCC”	Hong Kong Securities Clearing Company Limited;
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC;
“Latest Practicable Date”	15 November 2024, being the latest practicable date prior to the printing of this circular for ascertaining certain information contained in this circular;
“Listing Committee”	the listing committee of the Stock Exchange for considering applications for listing and the granting of listing of securities on the Stock Exchange;

DEFINITIONS

“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange, as amended from time to time;
“Main Board”	the Main Board of the Stock Exchange;
“PRC”	The People’s Republic of China which shall, for the purpose of this circular, exclude the Hong Kong Special Administrative Region of the PRC, the Macau Special Administrative Region of the PRC and Taiwan;
“Share(s)”	ordinary share(s) of par value of HK\$0.01 each in the capital of the Company;
“Shareholder(s)”	holder(s) of the Share(s) or Subdivided Share(s), as the case may be;
“Share Option(s)”	option(s) to subscribe for Share(s) granted by the Company in accordance with the Share Option Scheme;
“Share Option Scheme”	share option scheme of the Company adopted on 29 December 2023 with 127,311,250 share options outstanding as at the Latest Practicable Date;
“Share Subdivision”	the proposed subdivision of each issued and unissued Share into four (4) Subdivided Shares;
“Stock Exchange”	The Stock Exchange of Hong Kong Limited; and
“Subdivided Share(s)”	ordinary share(s) of par value of one fourth Hong Kong cent each in the share capital of the Company upon the Share Subdivision becoming effective.

LETTER FROM THE BOARD

Jinhai Medical Technology Limited

今海醫療科技股份有限公司

(Incorporated in the Cayman Islands with members' limited liability)

(Stock Code: 2225)

Executive Directors:

Mr. Chen Guobao (*Chairman*)
Mr. Wang Zhenfei (*Chief Executive Officer*)
Mr. Li Yunping
Mr. Dai Yong

Non-executive director:

Mr. Wang Huasheng

Independent non-executive directors:

Mr. Yan Jianjun
Mr. Fan Yimin
Ms. Yang Meihua

Registered Office:

Vistra (Cayman) Limited
P.O. Box 31119
Grand Pavilion, Hibiscus Way
802 West Bay Road, Grand Cayman
KY1-1205 Cayman Islands

***Head office and principal place
of business in Singapore:***

31 Sungei Kadut Avenue
Singapore 729660

***Principal place of business
in Hong Kong:***

3rd Floor, GF Tower
81 Lockhart Road
Wan Chai, Hong Kong

22 November 2024

To the Shareholders

Dear Sir or Madam,

**PROPOSED SUBDIVISION OF SHARES;
AND
NOTICE OF EXTRAORDINARY GENERAL MEETING**

INTRODUCTION

References are made to the announcement of the Company dated 1 November 2024 in relation to, *inter alia*, the Share Subdivision.

The purpose of this circular is to provide the Shareholders with the notice of EGM and the details of the Share Subdivision.

PROPOSED SHARE SUBDIVISION

The Board proposes to subdivide each of the existing issued and unissued Shares of par value of one Hong Kong cent each in the share capital of the Company into four (4) Subdivided Shares of par value of one fourth Hong Kong cent each.

LETTER FROM THE BOARD

Effects of the Share Subdivision

As at the Latest Practicable Date, the authorised share capital of the Company is HK\$20,000,000 divided into 2,000,000,000 Shares of one Hong Kong cent each, of which 1,292,500,000 Shares have been issued and are fully paid or credited as fully paid.

Upon the Share Subdivision becoming effective, the authorised share capital of the Company will be HK\$20,000,000 divided into 8,000,000,000 Subdivided Shares of par value of one fourth Hong Kong cent each, of which 5,170,000,000 Subdivided Shares will be in issue and fully paid or credited as fully paid, assuming that no further Shares are issued or repurchased prior to the Share Subdivision becoming effective.

The Shares are currently traded in board lot size of 5,000 Shares. Upon the Share Subdivision becoming effective, the board lot size of the Subdivided Shares for trading on the Stock Exchange will remain as 5,000 Subdivided Shares.

All Subdivided Shares will rank *pari passu* with each other in all respects with, and will have the same rights and privileges as, the Shares in issue prior to the Share Subdivision, and the Share Subdivision will not result in any change in the relevant rights of the Shareholders. As the Share Subdivision will not result in any odd lots or fractional shares, no odd lots arrangement for matching the sale and purchase of odd lots will be made.

Securities convertible or exchangeable into Shares

As at the Latest Practicable Date, the Company has 127,311,250 outstanding Share Options granted under the Share Option Scheme to subscribe for an aggregate of 127,311,250 Shares. Upon the Share Subdivision becoming effective, pro-rata adjustments will be made to the exercise prices and the number of outstanding Share Options. The Company will inform each of the grantees of the Share Options regarding the adjustments to be made pursuant to the respective terms and conditions of the Share Option Scheme.

Save as disclosed above, as at the Latest Practicable Date, the Company does not have any options outstanding under any share option scheme of the Company or any other derivatives, options, warrants and conversion rights or other similar rights which are convertible or exchangeable into Shares.

Dealings of the Subdivided Shares

The Subdivided Shares will be identical in all respects and rank *pari passu* in all respects with each other as to all future dividends and distributions which are declared, made or paid. Subject to the granting of the listing of, and permission to deal in, the Subdivided Shares and all Subdivided Shares which may fall to be issued upon the exercise of Share Options to be granted from time to time under the Share Option Scheme, such Subdivided Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from

LETTER FROM THE BOARD

the commencement date of dealings in the Subdivided Shares on the Stock Exchange or such other date as determined by HKSCC. Settlement of transactions between participants of the Stock Exchange on any trading day is required to take place in CCASS on the second settlement day thereafter. All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time.

Conditions of the Share Subdivision

The Share Subdivision is conditional upon:

- (a) the passing by the Shareholders at the EGM of an ordinary resolution approving the Share Subdivision;
- (b) the Stock Exchange granting the listing of, and permission to deal in, the Subdivided Shares and any new Subdivided Share which may be issued upon the exercise of the Share Options granted or to be granted from time to time under the Share Option Scheme; and
- (c) the compliance with all relevant procedures and requirements under the laws of the Cayman Islands (where applicable) and the Listing Rules to effect the Share Subdivision.

The Share Subdivision will become effective after the conditions of the Share Subdivision above are fulfilled.

Listing application

An application will be made by the Company to the Stock Exchange for the listing of, and the permission to deal in, (i) the Subdivided Shares; and (ii) any new Subdivided Share which may be issued upon the exercised of the Share Options granted or to be granted from time to time under the Share Option Scheme.

Subject to the granting of the listing of, and permission to deal in, the Subdivided Shares on the Stock Exchange, the Subdivided Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the commencement date of dealings in the Subdivided Shares on the Stock Exchange or such other date as determined by HKSCC. Settlement of transactions between participants of the Stock Exchange on any trading day is required to take place in CCASS on the second settlement day thereafter. All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time.

LETTER FROM THE BOARD

No part of the securities of the Company is listed or dealt in or on which listing or permission to deal is being or is proposed to be sought on any other stock exchanges other than the Stock Exchange and no such listing permission to deal in is being or currently proposed to be sought from any other stock exchanges.

Exchange of Share Certificates

Subject to the Share Subdivision having become effective, the share certificates adopted by the Company under its current name, “Jinhai Medical Technology Limited”, and former names being “Jinhai International Group Holdings Limited” and “Kakiko Group Limited” (together, the “**Existing Share Certificates**”) will only be valid for delivery, trading and settlement purposes for the period up to 4:10 p.m. on Monday, 20 January 2025 and thereafter will not be accepted for delivery, trading and settlement purposes. However, the Existing Share Certificates will continue to be good evidence of legal title to the Subdivided Shares on the basis of one (1) Share for four (4) Subdivided Shares.

Upon the Share Subdivision becoming effective, the Shareholders can submit their existing certificates for the Shares to the Company’s branch share registrar and transfer office, Boardroom Share Registrars (HK) Limited at Room 2103B, 21/F, 148 Electric Road, North Point, Hong Kong, in exchange for the new share certificates for the Subdivided Shares free of charge between 9:00 a.m. and 4:30 p.m. on any Business Day from Thursday, 12 December 2024 to Wednesday, 22 January 2025 (both days inclusive). After the expiry of such period, the existing certificates for the Shares will be accepted for exchange only on payment of a fee of HK\$2.50 (or such higher amount as may from time to time be specified by the Stock Exchange) for each Existing Share Certificates cancelled or new share certificate issued (whichever number of share certificates involved is higher). It is expected that the new share certificates for the Subdivided Shares will be available for collection within a period of 10 Business Days after the submission of the Existing Share Certificates for the Shares to Boardroom Share Registrars (HK) Limited for exchange.

The new share certificates will be yellow in colour so as to be distinguished from the Existing Share Certificates which are pink (in respect of the certificates in former name of the Company “Kakiko Group Limited”) or blue (in respect of the certificates in former name of the Company “Jinhai Jinhai International Group Holdings Limited”) or in red (in respect of the certificates in current name of “Jinhai Medical Technology Limited”) colours.

REASON FOR THE SHARE SUBDIVISION

The proposed Share Subdivision will reduce the nominal value or par value and trading price of each Share and increase the number of Shares in issue. As a result, the Share Subdivision is expected to reduce the trading price of each Share in the Company correspondingly which would appeal to more investors. Based on the closing price of HK\$8.77 per Share as at the Latest Practicable Date, (i) the market value per board lot of 5,000 Shares is HK\$43,850; and (ii) the value of each board lot of 5,000 Subdivided Shares, with a theoretical

LETTER FROM THE BOARD

adjusted price of approximately HK\$2.19 per Subdivided Share assuming the Share Subdivision had already become effective, would be approximately HK\$10,950. Although the Share Subdivision will result in downward adjustment to the trading price of the Shares, the Board believes that the Share Subdivision would enhance the liquidity in trading of Shares and thereby would enable the Company to attract more investors and broaden its Shareholder base. Accordingly, the Board considers that the Share Subdivision is in the interest of the Company and its Shareholders as a whole.

The Directors have considered alternative ratios for the proposed Share Subdivision, which are ratios smaller than that of the proposed Share Subdivision. Yet, having considered the price and the trading volume of the Shares for the past two years, the Directors are of the view that a trading price in the range of approximately HK\$1.5 to HK\$2 per Subdivided Share and a market value per board lot of 5,000 Subdivided Shares in the range of approximately HK\$7,500 to HK\$10,000 can best achieve the intended effect of the Share Subdivision in lowering the investment barrier of the investors of the Company and maximising liquidity in the trading of shares of the Company, while ensuring the trading price and the market value per board lot of the shares of the Company each remains substantially higher, and safe from becoming lower than HK\$0.1 (pursuant to the Guide (as defined below), market price per share at a level less than HK\$0.1 will be considered by the Stock Exchange as approaching the extremities of HK\$0.01 as referred to under Rule 13.64 of the Listing Rules) and HK\$2,000 as respectively required under the Listing Rules and the “Guide on Trading Arrangements for Selected Types of Corporate Actions” issued by the Hong Kong Exchanges and Clearing Limited on 28 November 2008 and last updated in September 2024 (the “**Guide**”, together with the Listing Rules, the “**Relevant Rules**”), so as to avoid incurring any additional costs for carrying out further corporate action(s) and trading arrangement(s) for re-complying with the Relevant Rules after the proposed Share Subdivision becomes effective. Moreover, the subdivision of one (1) Share into four (4) Subdivided Shares would not create any odd lots to the Shareholders. Having taken into account the intended effect of the proposed Share Subdivision, the requirements of the Relevant Rules as well as the potential creation of odd lots, the Directors considered that the proposed subdivision of every existing Share into four (4) Subdivided Shares would be in the interest of the Company and the Shareholders as a whole.

As at the Latest Practicable Date, the Directors confirm that the Company (i) does not have any agreement, arrangement, understanding, intention, negotiation (concluded or otherwise) on any potential equity fund raising activities; and (ii) has no intention to carry out other corporate action which may have an effect of undermining or negating the intended purpose of the Share Subdivision in the coming twelve (12) months.

Having considered the Company’s current plan in relation to all corporate actions and equity fund raising activities for the next twelve (12) months, the Directors are of the view that the Share Subdivision is reasonable and sufficient and in the best interests of the Company and Shareholders as a whole.

LETTER FROM THE BOARD

Save for the expenses to be incurred by the Company in relation to the Share Subdivision, the implementation of the Share Subdivision will not, by itself, alter the underlying assets, business operations, management or the financial position of the Company or the proportionate interest of the Shareholders.

CLOSURE OF REGISTER OF MEMBERS

The register of members of the Company will be closed from Monday, 9 December 2024 to Tuesday, 10 December 2024, both days inclusive, during which period no transfer of Shares can be registered. In order to qualify for attending and voting at the EGM, all transfers of Shares accompanied by the relevant share certificates must be lodged with the Company's branch share registrar in Hong Kong, Boardroom Share Registrars (HK) Limited at Room 2103B, 21/F, 148 Electric Road, North Point, Hong Kong for registration not later than 4:30 p.m. on Friday, 6 December 2024.

EGM

A notice of the EGM is set out on pages 12 to 13 of this circular.

A form of proxy for use at the EGM is enclosed. Whether or not you are able to attend the EGM, you are requested to complete, sign and return the accompanying form of proxy in accordance with the instructions printed thereon to the Company's branch share registrar in Hong Kong, Boardroom Share Registrars (HK) Limited at Room 2103B, 21/F, 148 Electric Road, North Point, Hong Kong, as soon as possible and in any event not less than 48 hours before the time appointed for the holding of the EGM (or any adjournment thereof). Completion and return of the form of proxy will not preclude you from attending and voting in person at the EGM (or any adjournment thereof) should you so wish.

VOTING BY WAY OF POLL

Pursuant to Rule 13.39(4) of the Listing Rules, the resolution put to vote at the EGM will be decided by poll and the Company will announce the results of the poll in the manner prescribed under Rule 13.39(5) of the Listing Rules. To the best knowledge, belief and information of the Directors having made all reasonable enquiries, no Shareholder is required under the Listing Rules to abstain from voting on the resolution regarding the Share Subdivision at the EGM.

LETTER FROM THE BOARD

RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein misleading.

RECOMMENDATION

The Directors consider that the proposed resolution set out in the notice of the EGM in relation to the Share Subdivision is in the interests of the Company and the Shareholders as a whole. Accordingly, the Directors recommend Shareholders to vote in favour of the relevant resolution to be proposed at the EGM.

GENERAL

Your attention is drawn to the additional information set out in the appendices to this circular.

By Order of the Board
Jinhai Medical Technology Limited
Chen Guobao
Chairman of the Board and executive Director

APPENDIX I EXPECTED TIMETABLE OF THE SHARE SUBDIVISION

The expected timetable for the implementation of the Share Subdivision is set out below:

Latest date and time for lodging transfer documents in order to qualify for attending and voting at the EGM 4:30 p.m. on Friday, 6 December 2024

Register of members of the Company closed for determining entitlements to attend and vote at the EGM Monday, 9 December 2024 to Tuesday, 10 December 2024 (both days inclusive)

Latest time for the lodging of the form of proxy for the EGM 3:00 p.m. on Sunday, 8 December 2024

Expected date and time of the EGM 3:00 p.m. on Tuesday, 10 December 2024

Announcement of voting results of the EGM Tuesday, 10 December 2024

The following events are conditional upon the fulfilment of the conditions for the implementation of the Share Subdivision as set out in the section headed “Conditions of the Share Subdivision” above.

The effective date for the Share Subdivision Thursday, 12 December 2024

Dealings in Subdivided Shares commence 9:00 a.m. on Thursday, 12 December 2024

Original counter for trading in board lots of 5,000 Shares temporarily closes 9:00 a.m. on Thursday, 12 December 2024

Temporary counter for trading in board lots of 20,000 Subdivided Shares (in form of Existing Share Certificates) opens 9:00 a.m. on Thursday, 12 December 2024

First day of free exchange of Existing Share Certificates for the new share certificates for the Subdivided Shares commences Thursday, 12 December 2024

APPENDIX I EXPECTED TIMETABLE OF THE SHARE SUBDIVISION

Original counter for trading in board lots of
5,000 Subdivided Shares
(in the form of new shares certificates) re-opens 9:00 a.m. on
Monday, 30 December 2024

Parallel trading in Subdivided Shares
(in the form of new share certificates) and
Shares (in form of Existing Share Certificates) commences 9:00 a.m. on
Monday, 30 December 2024

Temporary counter for trading in Subdivided Shares
in board lots of 20,000 Subdivided Shares
(in the form of Existing Share Certificates) closes 4:10 p.m. on
Monday, 20 January 2025

Parallel trading in Subdivided Shares
(in the form of new share certificates) and
Shares (in form of Existing Share Certificates) ends 4:10 p.m. on
Monday, 20 January 2025

Free exchange of Existing Share Certificates for
new certificates ends 4:30 p.m. on
Wednesday, 22 January 2025

NOTICE OF EXTRAORDINARY GENERAL MEETING

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.

Jinhai Medical Technology Limited

今海醫療科技股份有限公司

(Incorporated in the Cayman Islands with members' limited liability)

(Stock Code: 2225)

NOTICE OF EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that an extraordinary general meeting (“**EGM**”) of Jinhai Medical Technology Limited (the “**Company**”) will be held at Block 3 East, 1275 Meichuan Road, Putuo District, Shanghai, China, on Tuesday, 10 December 2024 at 3:00 p.m. for the following purposes:

ORDINARY RESOLUTION

1. “**THAT** subject to and conditional upon (i) the Listing Committee of The Stock Exchange of Hong Kong Limited granting the listing of, and permission to deal in, the Subdivided Shares (as defined below) and any new Subdivided Share which may be issued upon the exercise of the share options to be granted from time to time under the share option scheme adopted by the Company on 29 December 2023; and (ii) the compliance with all relevant procedures and requirements under the laws of the Cayman Islands (where applicable) and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited to effect the Share Subdivision (as defined below), each of the issued and unissued ordinary shares of nominal value of HK\$0.01 each of the Company be and is hereby subdivided into four (4) ordinary shares of nominal value of HK\$0.0025 each of the Company (the “**Subdivided Shares**”), with effect from 12 December 2024 (the “**Share Subdivision**”), and that any director of the Company (the “**Director**”) be and is hereby authorised for and on behalf of the Company to execute all such documents, instruments and agreements and to do all such acts or things deemed by the Director in his/her absolute discretion to be incidental to, ancillary to or in connection with the matters contemplated in and/or for implementation of the Share Subdivision including but not limited to, cancelling any existing share certificates and issuing new share certificates in respect of the Subdivided Shares to holders of the existing shares of the Company pursuant to the Share Subdivision.”

By Order of the Board

Jinhai Medical Technology Limited

Chen Guobao

Chairman of the Board and executive Director

Hong Kong, 22 November 2024

NOTICE OF EXTRAORDINARY GENERAL MEETING

Notes:

1. A member entitled to attend and vote at the meeting shall be entitled to appoint another person as his proxy to attend and, on a poll, vote in his stead. A member who is the holder of two or more shares of the Company (“**Shares**”) may appoint more than one proxy to represent him and, on a poll, vote on his behalf. A proxy need not be a member of the Company.
2. In order to be valid, a proxy form together with any power of attorney or other authority (if any) under which it is signed or a notarially certified copy of that power or authority, must be deposited at the Company’s branch share registrar in Hong Kong, Boardroom Share Registrars (HK) Limited at Room 2103B, 21/F, 148 Electric Road, North Point, Hong Kong not less than 48 hours before the time for holding the meeting (or any adjournment thereof).
3. The register of members of the Company will be closed from Monday, 9 December 2024 to Tuesday, 10 December 2024, both days inclusive, during which period no transfer of Shares can be registered. In order to qualify for attending and voting at the EGM, all transfers of Shares accompanied by the relevant share certificates must be lodged with the Company’s branch share registrar in Hong Kong, Boardroom Share Registrars (HK) Limited at Room 2103B, 21/F, 148 Electric Road, North Point, Hong Kong for registration not later than 4:30 p.m. on Friday, 6 December 2024.
4. Pursuant to Rule 13.39(4) of the Listing Rules, the resolution put to vote at the EGM will be decided by poll and the Company will announce the results of the poll in the manner prescribed under Rule 13.39(5) of the Listing Rules.
5. In the case of joint holders of a share, any one of such holders may vote at the meeting, either personally, by proxy, in respect of such shares as if he were solely entitled thereto but if more than one of such joint holders be present at the meeting personally or by proxy, that one of such holders so present whose name stands first on the register of members in respect of such share shall alone be entitled to vote in respect thereof.
6. As at the date of this notice, the Board comprises eight Directors, of which four are executive Directors, namely Mr. Chen Guobao, Mr. Wang Zhenfei, Mr. Li Yunping and Mr. Dai Yong; one is non-executive Director, namely Mr. Wang Huasheng; and three are independent non-executive Directors, namely Mr. Yan Jianjun, Mr. Fan Yimin and Ms. Yang Meihua.